Adjuvant and neoadjuvant therapies in high risk localized prostate cancer

被引：0
|
作者：
Giannakopoulos, X.
Stagikas, D.
Charalabopoulos, A.
Sofikitis, N.
Charalabopoulos, K.
机构：
[1] Univ Ioannina, Dept Physiol, Clin Unit, Fac Med, GR-45221 Ioannina, Greece
[2] Univ Ioannina, Dept Urol, GR-45221 Ioannina, Greece
[3] Peterborough Hosp, Dept Surg, Peterborough, Cambs, England
来源：
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH | 2006年 / 25卷 / 04期
关键词：
prostate cancer; adjuvant therapy; neoadjuvant therapy;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
In this review article adjuvant and neoadjuvant therapies in patients at high risk for localized prostate cancer are presented in some detail. Adjuvant hormone therapy by antiandrogens as well as antineoplastic chemotherapeutic agents such as estramustine and taxanes are referred. Neoadjuvant therapies in addition to systemic therapy before or after local treatment for prostate cancer may improve the outcome of high risk patients otherwise destined to treatment fail. Data regarding some substances used in neoadjuvant therapies such as androgen deprivation therapy and use of rapamycin with its analogs, as well as some novel therapeutic approach strategies are also discussed.
引用
收藏
页码：469 / 473
页数：5
相关论文
共 50 条
  • [31] Multimodality Therapies for Localized Prostate Cancer
    Valle, Luca F.
    Jiang, Tommy
    Weiner, Adam B.
    Reiter, Robert E.
    Rettig, Matthew B.
    Shen, John
    Chang, Albert J. J.
    Nickols, Nicholas G.
    Steinberg, Michael L.
    Kishan, Amar U.
    CURRENT ONCOLOGY REPORTS, 2023, 25 (03) : 221 - 229
  • [32] Multimodality Therapies for Localized Prostate Cancer
    Luca F. Valle
    Tommy Jiang
    Adam B. Weiner
    Robert E. Reiter
    Matthew B. Rettig
    John Shen
    Albert J. Chang
    Nicholas G. Nickols
    Michael L. Steinberg
    Amar U. Kishan
    Current Oncology Reports, 2023, 25 : 221 - 229
  • [33] Alternative therapies for localized prostate cancer
    Harrie P. Beerlage
    Current Urology Reports, 2003, 4 (3) : 216 - 220
  • [34] Neoadjuvant and adjuvant chemohormonal therapy in patients with high-risk and very high-risk prostate cancer: our experience
    Ustinova, T., V
    Nyushko, K. M.
    Bolotina, L., V
    Kharchenko, N., V
    Paychadze, A. A.
    Taraki, I. A.
    Alekseev, B. Ya
    Krasheninnikov, A. A.
    Kaprin, A. D.
    ONKOUROLOGIYA, 2018, 14 (03): : 58 - 67
  • [35] Randomized phase II trial of neoadjuvant everolimus in patients with high-risk localized prostate cancer
    Koshkin, Vadim S.
    Mir, Maria C.
    Barata, Pedro
    Gul, Anita
    Gupta, Ruby
    Stephenson, Andrew J.
    Kaouk, Jihad
    Berglund, Ryan
    Magi-Galluzzi, Cristina
    Klein, Eric A.
    Dreicer, Robert
    Garcia, Jorge A.
    INVESTIGATIONAL NEW DRUGS, 2019, 37 (03) : 559 - 566
  • [36] What is appropriate neoadjuvant/adjuvant androgen deprivation for high-risk/locally advanced prostate cancer?
    Namiki, Mikio
    Konaka, Hiroyuki
    ASIAN JOURNAL OF ANDROLOGY, 2011, 13 (04) : 624 - 625
  • [37] Randomized phase II trial of neoadjuvant everolimus in patients with high-risk localized prostate cancer
    Vadim S. Koshkin
    Maria C. Mir
    Pedro Barata
    Anita Gul
    Ruby Gupta
    Andrew J. Stephenson
    Jihad Kaouk
    Ryan Berglund
    Cristina Magi-Galluzzi
    Eric A. Klein
    Robert Dreicer
    Jorge A. Garcia
    Investigational New Drugs, 2019, 37 : 559 - 566
  • [38] Neoadjuvant Systemic Therapy Prior to Radical Prostatectomy for Clinically Localized High-Risk Prostate Cancer
    Perera, Marlon
    Beech, Benjamin B.
    Escano, Manuel De Jesus
    Gmelich, Caroline
    Yip, Wesley
    Boorjian, Stephen A.
    Eastham, James A.
    FRONTIERS IN UROLOGY, 2022, 2
  • [39] Neoadjuvant Therapy in High-Risk Prostate Cancer
    Ashrafi, Akbar N.
    Yip, Wesley
    Aron, Monish
    INDIAN JOURNAL OF UROLOGY, 2020, 36 (04) : 251 - 261
  • [40] Adjuvant docetaxel for high-risk localized prostate cancer: Update of NRG Oncology/RTOG 0521
    Sandler, Howard M.
    Karrison, Theodore
    Sartor, A. Oliver
    Gomella, Leonard G.
    Amin, Mahul B.
    Purdy, James
    Michalski, Jeff M.
    Garzotto, Mark
    Pervez, Nadeem
    Balogh, Alexander G.
    Rodrigues, George
    Souhami, Luis
    Reaume, M. Neil
    Williams, Scott
    Hannan, Raquibul
    Jones, Christopher U.
    Horwitz, Eric M.
    Rodgers, Joseph P.
    Feng, Felix Y.
    Rosenthal, Seth A.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
12345